Published in Gene Therapy Weekly, April 6th, 1998
The agreement further leverages Oncormed's strengths in gene characterization and pharmacogenomics with Affymetrix' GeneChip expression analysis tools. The latest collaboration is the third in a series of agreements between the companies, representing a relationship that began with the development and validation of a GeneChip assay for identifying mutations in the p53 gene.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.